Lidocaine for Tinnitus Relief: A Review

Roughly 15% of the global population experiences tinnitus, the perception of sound without an external source. For decades, researchers have searched for a pharmacological solution to quiet the persistent ringing or buzzing. One candidate, the local anesthetic lidocaine, has shown flashes of promise. A new systematic review and meta-analysis led by Anas Alashram synthesizes the evidence on lidocaine’s effects, concluding that while there may be temporary benefits for specific symptoms, the overall picture remains unclear.

### How Researchers Investigated Lidocaine’s Impact

Alashram’s team conducted a comprehensive search of major scientific databases, including PubMed and Cochrane, up to November 2025. They focused exclusively on randomized controlled trials, the gold standard for clinical evidence, where lidocaine was administered to people with tinnitus and symptoms were formally assessed. The review ultimately included 12 studies with a total of 550 participants. Each study was evaluated for potential bias using the Cochrane Risk of Bias 2 tool; four were rated as low risk, while eight raised some concerns, primarily around how outcomes were measured or reported.

The analysis looked at different ways lidocaine was given—primarily intravenously (IV) or via intratympanic injection directly into the middle ear—and measured outcomes using standardized tools like the Tinnitus Handicap Inventory (THI) and visual analog scales (VAS) for loudness and intensity.

### Meta-Analysis Shows No Clear Win for Severity

The core finding from pooling the data is decisive. Lidocaine did not produce a statistically significant reduction in overall tinnitus severity. The meta-analysis for THI scores showed a mean effect size of 0.358, but the confidence interval crossed zero (95% CI: -0.092 to 0.809), meaning the result could be due to chance. Similarly, for VAS-measured tinnitus intensity, the effect size was 0.145 (95% CI: -0.398 to 0.687). Both results were not significant, with high statistical heterogeneity (I² = 77-79%) indicating substantial differences between the study outcomes.

This lack of a clear, consistent effect on the primary measures of severity is a major reason the review authors label the evidence as inconclusive. It suggests lidocaine is not a reliable, broad-spectrum treatment for reducing the overall burden of tinnitus as captured by these standard questionnaires.

### Hints of Benefit for Specific Symptoms

Despite the negative primary outcome, the review did identify signals of more targeted, temporary effects. Several studies indicated that both IV and intratympanic lidocaine might reduce the perceived pitch of tinnitus, lower its loudness, and decrease the associated distress. Intriguingly, some evidence pointed to a possible improvement in pure-tone hearing thresholds following administration.

These findings suggest lidocaine’s action as a sodium channel blocker, which reduces abnormal neuronal excitability, may temporarily disrupt the maladaptive neural activity thought to underlie tinnitus perception. The transient nature of these effects aligns with lidocaine’s short half-life and mirrors the short-term approach of other neuromodulation for tinnitus techniques. However, the high heterogeneity between studies—driven by different doses, administration routes, and patient populations—makes it difficult to draw firm clinical conclusions from these secondary benefits.

### Practical Implications and Future Research Directions

For clinicians and patients, this review underscores a cautious approach. Lidocaine, particularly given intravenously, is not a routine or approved treatment for tinnitus and carries potential side effects. The inconsistent evidence does not support its widespread use. However, the hints of activity on specific symptoms like pitch and loudness justify further investigation.

Future research needs to address the heterogeneity problem. Standardized protocols for lidocaine administration (dose, route, frequency) and consistent, high-quality outcome measures are essential. Researchers might also explore whether lidocaine could act as a “reset” tool for other therapies, perhaps creating a temporary window of reduced tinnitus perception during which coordinated reset stimulation or structured sound therapy could be more effective. Understanding which patient subgroups, if any, respond best to lidocaine is another critical question.

It is also worth noting that tinnitus rarely exists in isolation. The distress lidocaine may temporarily reduce is often intertwined with tinnitus, anxiety, and sleep problems, a complex cycle that typically requires a multifaceted management strategy beyond any single medication.

### A Promising Lead, But Not a Proven Path

The systematic review by Alashram provides a necessary, sobering consolidation of the evidence on lidocaine for tinnitus. The promise of temporary relief for certain symptoms is balanced by a lack of proven effect on overall severity and considerable uncertainty due to varied study methods. For now, lidocaine remains an interesting piece of the neuropharmacological puzzle, but not a clinical solution. Its story highlights the broader challenge in tinnitus treatment: finding an intervention that is not only effective but also durable and reliable for a condition that manifests so differently from person to person.

**Source Paper:** Alashram, A. *Effects of lidocaine on tinnitus symptoms: a systematic review and meta-analysis*. DOI: [10.1186/s43163-026-01130-3](https://doi.org/10.1186/s43163-026-01130-3)